CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity
Fig 2
NK cells, CD4 T cells, and CD8 T cells contribute to the anti-tumor activity of hCD38-mAtt and in extending overall survival of treated mice in the 38C13-hCD38 tumor model.
C3H (C3H/HeNCrl) mice bearing 38C13-hCD38 tumors were randomized into different treatment groups when tumors reached an average volume of ~ 100 mm3. One day prior to treatment (day -1), and every 7 days thereafter, mice were administered depleting αCD4, αCD8, or αAsialo GM-1 antibodies at doses shown to effectively and specifically deplete these cell populations [15–17]. On day 0, mice were administered 7 mg/kg hCD38-mAtt or PBS vehicle (equivalent final volume of 200 µ L) twice weekly by intraperitoneal injection for up to six doses. P-values were calculated using Log-rank (Mantel-Cox) test comparing each depletion treatment arm to vehicle or hCD38-mAtt, as indicated.